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CBackground: Disease registries are an important source of informa-
tion on the natural history of rare diseases and the response to new
therapies in a real-world setting. The value of the information, how-
ever, is directly related to the completeness of the data entered for
each patient over the course of time. The Fabry Outcome Survey
(FOS) is a Shire Human Genetic Therapies–sponsored, physician-
directed registry of patients with Fabry disease, a rare, multisystem,
lysosomal storage disorder, established in 2001. Objective and
Methods: In 2005, measures were introduced to improve the com-
pleteness of data capture, including a focus on centers with 20 or
more patients enrolled in the FOS, concentration on a limited num-
ber of core variables (i.e., serum creatinine, urinary protein, left ven-
tricular mass [echocardiography], blood pressure [systolic and dia-
stolic], pain, quality of life, and other Fabry disease–related signs O
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nd M
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oi:10.1016/j.jval.2011.05.002nd symptoms, as well as height and weight) and the introduction of
linical Project Associates (CPAs) to facilitate data management by
articipating treatment centers. Results: An analysis of random
amples of approximately 25% of patients in the registry in 2008
howed significant increases in data capture for most of the core
ariables examined. Conclusions: We conclude that the measures
ntroduced in 2005 significantly improved the value of the informa-
ion in the registry, which has contributed greatly to our under-
tanding of patients’ real-world experience with enzyme replace-
ent therapy for Fabry disease.
eywords: agalsidase alfa, Fabry disease, observational studies, out-
ome surveys, patient registries.
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utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Randomized, controlled trials (RCTs), performed primarily to es-
tablish the efficacy and safety of specific therapeutic interven-
tions, are usually considered to be the gold standard of research
evidence. There is an increasing need, however, for real-world
clinical data on effectiveness, driven by health-care professionals,
third-party payers such as public drug reimbursement programs
and private insurers, and regulatory authorities [1–3]. This is, in
part, because the restrictive and experimental environment of an
RCT does not allow for exploration of the course of a disease over
a prolonged period, confirmation of treatment effectiveness, or
assessment of treatment cost, value, or impact in an everyday
context in a wider patient population [4]. Although RCTs generally
measure the short-term efficacy of an intervention in limited,
strictly defined patient populations, observational studies can al-
low the exploration of broader, heterogeneous, and more repre-
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ublished by Elsevier Inc.sentative groups over longer periods of time [1,5–7]. Such studies,
therefore, enable assessment of the effectiveness and long-term
safety of interventions in clinical practice, using clinically relevant
end points rather than the short-term surrogate end points often
used in RCTs [1,6].
Patient registries are particularly useful for gathering informa-
tion about rare diseases, for example, the lysosomal storage dis-
orders (LSDs). As registries collect data over long time periods and
for a greater number of patients, a more complete picture of the
evolution of disease and real-world experience with therapeutic
interventions can be developed. The value of the information from
such registries, however, is directly related to the completeness of
the data that have been entered over time.
The Fabry Outcome Survey (FOS) was established in 2001 to
collect data on an ongoing basis from a large group of patients with
Fabry disease (FD) to improve our understanding of the natural
history of the disease and to evaluate the long-term effectiveness
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alfa [8]. FD is a rare, X-linked LSD, caused by deficiency of the
enzyme alpha-galactosidase A. It is characterized by progressive
renal impairment, hypertrophic cardiomyopathy, and stroke as
well as nonlethal complications of other systems [8]. FD patients
also usually experience chronic pain, which markedly impairs
their quality of life [9–13]. Historically, female carriers of alpha-
galactosidase A mutations were thought to be free of the symp-
toms or medical complications of the disease. However, as many
as 75% experience pain and gastrointestinal complaints as well as
the serious end-organ damage characteristic of FD [14]. The age at
onset of symptoms and the age at which serious complications
develop in female carriers,is later than that in affected males. In
children, affected boys generally begin to report pain and gastro-
intestinal problems, such as abdominal pain and diarrhea, before
the age of 10 years, although the diagnosis is often delayed for
years because of the nonspecific nature of the complaints and the
absence of physical signs [12].
Collecting data via a patient registry and its subsequent inter-
pretation present a number of challenges, including ensuring that
data capture is complete for enrolled patients. In this article, we
discuss measures taken to enhance data capture by the FOS and
the impact these have had on the completeness of data on the
effectiveness of ERT for FD in a real-world setting.
Methods
Data collection and structure
Patients are eligible for entry into the FOS if they have received a
diagnosis of FD and are untreated or are receiving ERT with agal-
sidase alfa. On enrollment in the FOS, a summary of the medical
history of a patient is documented, including the year of diagnosis,
demographic details, family history, and details of treatment.
Signs and symptoms are recorded using an extensive checklist
that covers the clinical manifestations of FD and includes 16 organ
systems [8,13].
All measurements entered into the FOS registry are observations
routinely recorded in the course of the clinical management of pa-
tients with FD, e.g., details of the diagnosis of FD (measurements of
alpha-galactosidase A activity andGLA gene mutation analysis), and
renal and cardiac function assessments. In addition, patients are reg-
ularly asked to complete questionnaires regarding health state, pain,
and health-related quality of life [13]. All data are anonymized by the
use of coded alphanumeric identifiers that can only be decoded by
the treatment center managing the patient and submitted electron-
ically by participating physicians and nurses to the central FOS reg-
istry. Institutional review boards or ethics committees at all partici-
pating centers have approved their involvement in the FOS, and all
patients provide written informed consent [8].
The development of the FOS and analyses of FOS data are driven
y the participating physicians. The FOS Executive Committee com-
rises five delegates from the International Board, along with the
utgoing Chairperson. This committee drives the development of
anuscripts and presentations from the FOS and works closely with
he Working Groups to ensure timely presentation of data.
Measures implemented to improve patient enrollment
The FOS Executive Committee has emphasized the importance of
discussing enrollment in the FOS with all patients who are eligible
for inclusion to ensure that the FOS reflects the spectrum of FD
patients, including those who do not receive ERT or family mem-
bers who have received a diagnosis of FD but show minimal clin-
ical symptoms (mainly women and children). In addition, efforts
have been made to engage with participating physicians through
the establishment of expert working groups, making data accessi-ble for analysis and regular communications at local, national, and
international meetings to ensure that physicians take ownership
of and pride in the data.
Measures implemented to improve data completeness and
quality
Beginning in 2006, three measures were implemented to improve
the collection and quality of data: 1) increased concentration on
centers that have enrolled 20 or more patients in the FOS, 2) focus
on a core set of particularly important variables, and 3) use of
Clinical Project Associates (CPAs), with financial support from
Shire Human Genetic Therapies, to monitor data capture and
quality at participating centers.
Increased concentration on centers with 20 or more patients
In 2007, the FOS Executive Committee recommended an increased
focus on centers with 20 or more patients enrolled. Larger centers
are usually more experienced in assessment of disease, and pa-
tients are thoroughly evaluated by a team covering a range of spe-
cialties, such as cardiology and nephrology; their size also facili-
tates effective monitoring.
Focus on a core set of particularly important variables
The FOS Executive Committee further recommended a core set
of 10 variables: serum creatinine, urinary protein, left ventricu-
lar mass (echocardiography), blood pressure (systolic and dia-
stolic), pain, quality of life, and other FD-related signs and
symptoms as well as height and weight. Pain and health-related
quality of life data were collected using patient-reported out-
come questionnaires: the Brief Pain Inventory and EuroQoL-5D,
respectively.
Use of CPAs
In 2007, CPAs with previous experience of clinical trial monitoring
were employed by Shire Human Genetic Therapies and assigned to
specific geographic locations to serve as the contact persons for the
centers, to regularly analyze data for inconsistencies, and to help
with training center staff on data entry. The FOS staff developed
guidelines for use by the CPAs, placing particular emphasis on the
core variables when examining the data for inconsistencies. Incon-
sistencies included missing data and extreme outliers (values lying
outside the range of possible values, defined by the Working Group
specialists and/or Shire physicians). The CPAs made regular visits to
the sites to examine the data and then provide targeted training
based on any inconsistencies found. Because the reviews by CPAs did
not include source document verification, as they would for an RCT,
data monitoring was restricted to a review for logical inconsistencies,
i.e., missing data and extreme outliers.
To assess the impact of these measures, a random sample of
approximately 25% of all patients enrolled in the FOS in 2005, includ-
ing those from centers with fewer than 20 patients, was identified,
and the completeness of core data entered was determined. Data
completeness refers to the percentage of the randomly selected pa-
tients who have at least one value recorded for each variable in each
year. A further analysis of a different random sample of 25% of FOS
patients was undertaken in 2008, 2 years after the implementation of
these changes. Subanalyses were performed on patients enrolled in
the FOS for 5 years, female patients, and children.
Results
Patient enrollment
A total of 132 centers in 21 countries have contributed data to the
FOS. As of December 2008, 1616 patients were enrolled (47.2%
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ber of female patients enrolled in the FOS has increased steadily
(Fig. 1), and women were found to be just as likely to have symp-
toms as men, although generally less severe [1].
Effect of implementing measures to improve collection and
quality of data
Increased concentration on centers with 20 or more patients
In March 2007, 114 centers were participating in the FOS. Of those,
20 were excluded from the analysis because they eventually be-
came inactive, and a further 10 were excluded because the data
sets collected could not be analyzed for inconsistencies. Of the
remaining 84 centers, 76 were assisted by CPAs and 17 had 20 or
more patients. The registry evolved with time, with more centers
being added each year. To compare differences between 2007 and
2010, only data from centers participating from the year 2007 were
used. The reason for centers becoming inactive is complex. In
many cases, the patients or their physicians may have moved,
with the result that data entry from the original center is inter-
rupted. The reasons for center inactivity in many cases are un-
known.
The overall percentage of inconsistencies in 2007 was 2.4%
(2597 inconsistencies out of 108,627 observations) compared to
0.8% in 2010 (1649 inconsistencies out of 215,144 observations, as
of July). The focus on centers with 20 or more patients enrolled has
improved the quality of data documented; despite more patients
and more data points at larger centers, similar decreases in the
percentage of inconsistencies were observed when compared
with smaller centers (Table 1).
Fig. 1 – Enrollment of male and female patients with FD as
of December 2008.
Table 1 – Comparison of per-center change in the
percentage of inconsistencies from March 2007 to July
2010 between centers with >20 versus <20 patients.
Variable n Mean (SD) Median (10th–90th
percentiles)
Centers with
20 patients
17 1.3 (1.22) 0.9 (2.9 to 0.2)
Centers with 67 1.8 (3.24) 0.5 (5.5 to 0.0)
20 patientsFocus on core variables
Random samples (approximately 25%) from all enrolled patients
of all centers were taken from the 2005 (n  197 of 815) and 2008
(n 404 of 1616) data sets to assess the impact of the data robust-
ess drive using SAS 9.1 software. When compared, an improve-
ent was found in the completeness of data across almost all data
et variables (Fig. 2). Additionally, there has been a large increase
n the number of patients of both sexes enrolled. Analysis of the
andomized data shows that the female ratio increased from 48%
o 54%.
Use of CPAs
Periodic review by the CPAs has led to important improvements
across most of the variables that composed the core data set.
Training of clinical personnel within each center also improved
the completeness and comprehensiveness of the data collected,
with recording of patients’ signs and symptoms at center visits
showing the greatest increase (26.7%) between 2007 and 2008
(Fig. 3).
A larger decrease in inconsistencies was observed in centers
with CPA assistance compared to centers that did not receive as-
Fig. 2 – Comparison of data completeness in FOS between
2005 (n=197) and 2008 (n=404). BP, blood pressure; BPI,
Brief Pain Inventory; ECHO, echocardiogram.
Fig. 3 – Comparison of data completeness in FOS between
2007 (n=1485) and 2008 (n=1616). BPI, Brief Pain Inventory.
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tance, however, makes it difficult to draw comparisons.
1. During 2008, the CPAs focused specifically on enhancing the
completeness of data in the following key groups: 1) patients who
have received treatment with agalsidase alfa for 5 years, 2) fe-
male patients who have received treatment with agalsidase alfa
for 3 years, and 3) children who have received treatment with
agalsidase alfa for 2 years.
The results are shown in Table 3. The reason for the disparate
improvement in data collection in the case of female patients
compared to males is unclear.
Discussion
The FOS is a Shire Human Genetic Therapies–sponsored, physi-
cian-driven, multicenter, international, observational survey
designed to provide a range of outcomes over the long term.
Three important sources of potential bias were identified during
the development of the FOS: bias in patient enrollment, incom-
pleteness of data, and uncertainty regarding data quality. Pa-
tients with less severe symptoms of FD are less likely to receive
a diagnosis and be enrolled in the FOS. This introduces a bias
toward patients with more severe disease [8]. In addition, 58% of
patients have received treatment with agalsidase alfa at some
point during their enrollment in the FOS. Treated patients may
also visit centers more regularly and be examined more rigor-
ously. As a result, there are fewer data for untreated patients,
the group most likely to provide information on the natural
history of FD. Furthermore, the inclusion of patients who are
already receiving therapy can introduce two types of bias: an
Table 2 – Comparison of per-center change in percentage
of inconsistencies fromMarch 2007 to July 2010 between
centers with and without CPA assistance.
Variable n Mean
(SD)
Median (10th–
90th percentiles)
Centers with CPA
assistance
76 1.8 (3.06) 0.8 (4.3 to 0.0)
Centers without CPA
assistance
8 0.5 (1.08) 0.4 (2.5 to 1.2)
CPA, Clinical Project Associate.
Table 3 – Improvements in the data measurement complet
and 2008.
Imp
Patients receiving agalsidase alfa
for 5 y (2007: N  1496; 2008:
N  1460), %
Fem
al
eGFR 2.8
Weight, kg 4.0
Urine protein, mg/24 h 1.9
Signs and symptoms 4.3
QoL score 4.2
MFS, % 5.6
LVM index, g/m2.7 5.6
Height, cm 0.0
BPI 4.1
BPI, Brief Pain Inventory; eGFR, estimated glomerular filtration rate;
available;.QoL, quality of life.underestimation of events that occur early during therapy and
an inability to control for disease risk factors that may be al-
tered by the intervention under investigation [15]. Efforts are
currently under way to achieve more complete enrollment in
the FOS of patients not prescribed treatment to gather informa-
tion on the course of disease in these patients.
An important source of uncertainty that was not addressed
in this study is a potential discrepancy between routine inves-
tigations undertaken by the treating physician as part of the
management of the patient and what was entered into the FOS
registry. Every effort was made to facilitate the entry of data;
however, it does take additional effort and time. Focusing on a
set of core data was a specific measure to simplify the entry of
data that exist, but might not otherwise be entered into the
registry. In addition, CPAs were recruited to drive the update of
prospective data. By focusing on centers that had enrolled at
least 20 patients in the FOS, the CPAs were able to increase the
completeness of data across all core variables. In an effort to
enhance the quality of data gathered, the scientific working
groups associated with the FOS are currently developing guide-
lines and frameworks to help improve consistency in the inter-
pretation of data between centers, and the FOS is establishing
centralized data interpretation of the results of imaging studies
to improve interobserver reliability of their analysis.
By prospectively collecting routine information on clinical
and patient-reported outcomes, the understanding of the natu-
ral history of FD and the long-term effectiveness and safety of
ERT with agalsidase alfa has been enhanced [16]. A recent pub-
lication from Mehta et al. [16] has shown that long-term treat-
ment with agalsidase alfa significantly improved cardiac struc-
ture (P  0.0111 in patients with baseline left ventricular
hypertrophy [LVH]) and function (P  0.02 at 3 years in patients
with baseline LVH), stabilized renal function, significantly re-
duced pain (P  0.0137 for worst pain), and significantly im-
roved quality of life (P  0.0483). Although the authors noted
hat this patient population may not be representative of the
eneral FD population, a sensitivity analysis undertaken in 475
atients who had at least one baseline and one follow-up as-
essment confirmed that the results reflected the wider popu-
ation. It is of some interest that the number of peer-reviewed
rticles published in peer-reviewed journals issuing from the
OS before 2006 and since the implementation of the changes
escribed here was 8 and 25, respectively, in addition to two
xtensive monographs on FD. The sample sizes reported in the
s in the three key groups within the FOS between 2007
ments in data collection
patients receiving agalsidase
r 3 y (2007: N  454; 2008:
N  459), %
Children receiving agalsidase
alfa for 2 y (2007: N  158;
2008:
N  154), %
11.9 2.7
10.5 2.8
20.0 7.1
16.5 1.6
17.6 4.8
19.5 n/a
18.8 2.5
4.4 1.8
16.5 n/a
midwall fractional shortening; LVM, left ventricular mass; n/a, notenes
rove
ale
fa fo
MFS,
866 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 6 2 – 8 6 6later articles were significantly greater than the numbers in-
cluded in earlier articles; the article published recently in the
Lancet [16] is a particularly noteworthy example of how im-
provements in the registry resulted in major advances in knowl-
edge.
Although the focus in this article has been on FD and the role of
registries in advancing knowledge of the natural history and re-
sponse to treatment of this rare LSD, the operational principles are
equally applicable to any rare disorder. The importance of regis-
tries in undertaking large-scale, long-term, observational studies
to assess the effectiveness of new therapies for rare diseases is
reflected in the growing interest of regulatory authorities in pa-
tient registries. For example, in response to this concern, the US
Agency for Healthcare Research and Quality has created the Effec-
tive Health Care program, a comprehensive user guide in which
the editors present a review of the purpose, design, and operation
of patient registries.
In summary, observational surveys, including patient regis-
tries, provide important experiential evidence that complements
that provided by RCTs, especially for rare disorders such as FD.
The data collected extend and enhance our understanding of
certain diseases and provide the foundation for the development
of measures to help optimize patient care and clinical outcomes.
Our study has shown the effect of measures undertaken to reduce
sources of bias and ensure that the data collected are complete
and of high quality.
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